Amgen Agrees To $200M Settlement Of Antitrust Suit
The agreement ends a long-running lawsuit in which Ortho Biotech, a unit of Johnson & Johnson, had claimed that Amgen's discounts to oncology clinics on two of its most popular oncology products, Neulasta and Neupogen, constituted an illegal tying arrangement to push sales of its anemia treatment Aranesp.
Aranesp is typically used to treat anemia caused by chemotherapy. Drugs like Aranesp and...
To view the full article, register now.